Psych · General adult psychiatry — psychotic disorders
Schizoaffective disorder
Also known as Schizoaffective · SAD bipolar type · SAD depressive type · Schizoaffective psychosis · Affective psychosis continuum
Exam-exhaustive fellowship reference on schizoaffective disorder — DSM-5-TR and ICD-11 operational criteria; bipolar versus depressive type; longitudinal discrimination from schizophrenia and bipolar with psychosis; antipsychotic foundation with mood-stabiliser and careful antidepressant use; suicide risk including InterSePT; course and RANZCP/APA/NICE-oriented guidance. FRANZCP-primary, globally tagged.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Cross-sectional psychosis plus low mood labelled schizoaffective without life-chart proof of mood majority and ≥2 weeks psychosis without mood — diagnostic error that drives polypharmacy
- Active suicidal intent or command content at the mood–psychosis interface — same-day senior review, means restriction, documented safety plan
- Bipolar-type schizoaffective treated with antidepressant monotherapy — switch and suicide risk
- New psychosis with fever, rigidity, fluctuating attention — exclude NMS, encephalitis and delirium before locking a primary label
- Valproate in people who can become pregnant without robust pregnancy-prevention framework — teratogenic emergency in planning
- Treatment-resistant psychosis after two adequate trials — do not endless-rotate non-clozapine antipsychotics when TRRIP criteria are met
Meet the patient
A 32-year-old man, four years unwell. Two manic admissions, several long depressions, and — his sister remembers this clearly — three separate fortnights when his mood was ordinary but he still heard a running commentary and believed cameras had been implanted in his flat.[1][19]
The intern's note reads: "Psychotic and depressed. Schizoaffective?" The consultant's question is the whole topic: "Show me the timeline that proves it."[1][2]
Cross-sectional labelling is the error that generates a decade of polypharmacy. Two duration rules stand between you and that mistake.[1][2]
References20ShowHide
- [1]Malaspina D, Owen MJ, Heckers S, et al. Schizoaffective Disorder in the DSM-5 Schizophr Res, 2013.PMID 23707642
- [2]Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders J Affect Disord, 2008.PMID 17719092
- [3]Lake CR, Hurwitz N Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease--there is no schizoaffective disorder Curr Opin Psychiatry, 2007.PMID 17551352
- [4]Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder J Clin Psychiatry, 2010.PMID 20492853
- [5]Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers J Clin Psychopharmacol, 2010.PMID 20814330
- [6]Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder J Clin Psychiatry, 2015.PMID 25562685
- [7]Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type J Affect Disord, 2001.PMID 11869760
- [8]Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 2003.PMID 12511175
- [9]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [10]Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders Aust N Z J Psychiatry, 2016.PMID 27106681
- [11]Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia Am J Psychiatry, 2020.PMID 32867516
- [12]Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet, 2013.PMID 23810019
- [13]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
- [14]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182
- [15]Howes OD, Kapur S The dopamine hypothesis of schizophrenia: version III--the final common pathway Schizophr Bull, 2009.PMID 19325164
- [16]Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population Arch Gen Psychiatry, 2007.PMID 17199051
- [17]Palmer BA, Pankratz VS, Bostwick JM The lifetime risk of suicide in schizophrenia: a reexamination Arch Gen Psychiatry, 2005.PMID 15753237
- [18]Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet, 2009.PMID 19595447
- [19]Grande I, Berk M, Birmaher B, et al. Bipolar disorder Lancet, 2016.PMID 26388529
- [20]Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5 Schizophr Res, 2013.PMID 23800613